Phage Therapy Pharmacology

被引:160
|
作者
Abedon, Stephen T. [1 ]
Thomas-Abedon, Cameron [1 ]
机构
[1] Ohio State Univ, Dept Microbiol, Mansfield, OH 44906 USA
关键词
Bacteriophages; ecology; pharmacodynamics; pharmacokinetics; INFECTIOUS-DISEASES-SOCIETY; BACTERIOPHAGE THERAPY; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; BACTERIAL BIOFILMS; LYSIS-INHIBITION; RESISTANT; KINETICS; REMOVAL;
D O I
10.2174/138920110790725410
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Phage therapy-application of bacteria-specific viruses to reduce densities of pathogenic or nuisance bacteria-is a two-step process involving phage penetration to target bacteria followed by bacteria killing. Any analysis of these steps is inherently ecological as they represent phage-environment interactions, i.e., between phages and bacteria as well as between phages and body tissues. In considering phages more generically, as selectively toxic antibacterial agents employed to treat bacterial infections, the term "ecology" may be fairly cleanly replaced with the term "pharmacology". Pharmacology, in turn, may be distinguished into two major components: pharmacokinetics and pharmacodynamics. Pharmacokinetics is explicitly a description of the body's impact on a drug (e.g., movement through and between body compartments) whereas pharmacodynamics is a description of a drug's impact on the body. "Body" includes both body tissues and microbial flora, so an important component of antibacterial pharmacodynamics is inhibition of the growth of target bacteria. Our guiding premise is that phage therapy may be rationally improved through a better understanding of phage pharmacokinetics and pharmacodynamics. Our primary conclusions are (i) that the principle advantages of phages, over antibiotics, are the former's relative safety and ease of discovery; (ii) that phage therapy efficacy is highly dependent on attaining relatively high phage "killing titers"; (iii) that attainment of sufficient titers solely via in situ phage replication should, in some or many circumstances, not be counted upon; and (iv) that phage replication nonetheless may provide a "margin of safety" toward attaining phage therapy efficacy.
引用
收藏
页码:28 / 47
页数:20
相关论文
共 50 条
  • [41] PHARMACOLOGY AND PHYSICAL THERAPY
    ROTHSTEIN, JM
    PHYSICAL THERAPY, 1995, 75 (05): : 341 - 341
  • [42] Phage-specific antibodies: are they a hurdle for the success of phage therapy?
    Washizaki, Ayaka
    Sakiyama, Arata
    Ando, Hiroki
    ESSAYS IN BIOCHEMISTRY, 2024,
  • [43] Phage as a Modulator of Immune Responses: Practical Implications for Phage Therapy
    Gorski, Andrzej
    Miedzybrodzki, Ryszard
    Borysowski, Jan
    Dabrowska, Krystyna
    Wierzbicki, Piotr
    Ohams, Monika
    Korczak-Kowalska, Grazyna
    Olszowska-Zaremba, Natasza
    Lusiak-Szelachowska, Marzena
    Klak, Marlena
    Jonczyk, Ewa
    Kaniuga, Ewelina
    Golas, Aneta
    Purchla, Sylwia
    Weber-Dabrowska, Beata
    Letkiewicz, Slawomir
    Fortuna, Wojciech
    Szufnarowski, Krzysztof
    Pawelczyk, Zdzislaw
    Rogoz, Pawel
    Klosowska, Danuta
    ADVANCES IN VIRUS RESEARCH, VOL 83: BACTERIOPHAGES, PT B, 2012, 83 : 41 - 71
  • [44] European regulatory aspects of phage therapy: magistral phage preparations
    Verbeken, Gilbert
    Pirnay, Jean-Paul
    CURRENT OPINION IN VIROLOGY, 2022, 52 : 24 - 29
  • [45] Toward phage therapy for tuberculosis
    Le Bras, Alexandra
    LAB ANIMAL, 2024, 53 (04) : 87 - 87
  • [46] Phage therapy for Pseudomonas aeruginosa
    Devi, Sharmila
    LANCET INFECTIOUS DISEASES, 2023, 23 (10): : E408 - E408
  • [47] Phage therapy: concept to cure
    Keen, Eric C.
    FRONTIERS IN MICROBIOLOGY, 2012, 3
  • [48] Animal Models of Phage Therapy
    Penziner, Samuel
    Schooley, Robert T.
    Pride, David T.
    FRONTIERS IN MICROBIOLOGY, 2021, 12
  • [49] Biotechnological challenges of phage therapy
    Skurnik, Mikael
    Pajunen, Maria
    Kiljunen, Saija
    BIOTECHNOLOGY LETTERS, 2007, 29 (07) : 995 - 1003
  • [50] Phage therapy: delivering on the promise
    Harper, D. R.
    Anderson, J.
    Enright, M. C.
    THERAPEUTIC DELIVERY, 2011, 2 (07) : 935 - 947